FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020813624> ?p ?o ?g. }

• W2020813624 endingPage "S102" @default.
• W2020813624 startingPage "S96" @default.
• W2020813624 abstract "Because clearance of hepatitis B virus (HBV) infection is rarely, if ever, achievable, the goals of therapy necessarily focus on prevention of bad clinical outcomes. Ideally, therapies would be shown to prevent tangible clinical endpoints like development of cirrhosis, end-stage liver disease and hepatocellular carcinoma. However, these endpoints typically take years or decades to occur and are therefore impractical targets for clinical trials which last only 1-2 years. As a result, surrogate biomarkers that are believed to correlate with long-term outcome are used to evaluate therapy. Of the clinical, biochemical, serological, virological, and histological endpoints that have been evaluated, none has been shown to be ideal on its own. Symptoms are uncommon and aminotransferase levels fluctuate spontaneously. Loss of hepatitis B e antigen (HBeAg) has been the traditional therapeutic endpoint; however, the indefinite durability off treatment and the emergence of HBeAg-negative disease have made it inadequate as the sole goal of therapy. Loss of hepatitis B surface antigen is associated with improved clinical outcomes, but it is rarely achieved with current therapies. Suppression of viral replication, as measured by serum HBV DNA levels, has become the major goal of therapy, particularly if maintained off therapy. Although useful, the significance of viral levels depends on the stage of disease, degree of liver damage, and the type of therapy. Finally, liver biopsy, often considered the gold standard, is invasive, prone to sampling error, and may take years to change significantly.At present, there is no ideal biomarker for evaluation of therapies for hepatitis B. Future research should be directed at development and validation of surrogate markers that accurately predict or reflect clinically relevant outcomes of chronic hepatitis B. (HEPATOLOGY 2009;49:S96–S102.)" @default.
• W2020813624 created "2016-06-24" @default.
• W2020813624 creator A5005263512 @default.
• W2020813624 creator A5049864482 @default.
• W2020813624 creator A5080846340 @default.
• W2020813624 date "2009-04-27" @default.
• W2020813624 modified "2023-10-03" @default.
• W2020813624 title "Endpoints of therapy in chronic hepatitis B" @default.
• W2020813624 cites W1986180586 @default.
• W2020813624 cites W1997865776 @default.
• W2020813624 cites W2000538721 @default.
• W2020813624 cites W2004054613 @default.
• W2020813624 cites W2004337218 @default.
• W2020813624 cites W2008132884 @default.
• W2020813624 cites W2008517556 @default.
• W2020813624 cites W2013716066 @default.
• W2020813624 cites W2023718741 @default.
• W2020813624 cites W2027498662 @default.
• W2020813624 cites W2047235770 @default.
• W2020813624 cites W2061217066 @default.
• W2020813624 cites W2068797382 @default.
• W2020813624 cites W2074118280 @default.
• W2020813624 cites W2076506726 @default.
• W2020813624 cites W2087991930 @default.
• W2020813624 cites W2094338286 @default.
• W2020813624 cites W2104389844 @default.
• W2020813624 cites W2105079980 @default.
• W2020813624 cites W2116390828 @default.
• W2020813624 cites W2123483039 @default.
• W2020813624 cites W2136336812 @default.
• W2020813624 cites W2151769300 @default.
• W2020813624 cites W2167596859 @default.
• W2020813624 cites W2170244859 @default.
• W2020813624 cites W2314866596 @default.
• W2020813624 doi "https://doi.org/10.1002/hep.22977" @default.
• W2020813624 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19399800" @default.
• W2020813624 hasPublicationYear "2009" @default.
• W2020813624 type Work @default.
• W2020813624 sameAs 2020813624 @default.
• W2020813624 citedByCount "73" @default.
• W2020813624 countsByYear W20208136242012 @default.
• W2020813624 countsByYear W20208136242013 @default.
• W2020813624 countsByYear W20208136242014 @default.
• W2020813624 countsByYear W20208136242015 @default.
• W2020813624 countsByYear W20208136242016 @default.
• W2020813624 countsByYear W20208136242017 @default.
• W2020813624 countsByYear W20208136242018 @default.
• W2020813624 countsByYear W20208136242019 @default.
• W2020813624 countsByYear W20208136242020 @default.
• W2020813624 countsByYear W20208136242021 @default.
• W2020813624 countsByYear W20208136242022 @default.
• W2020813624 crossrefType "journal-article" @default.
• W2020813624 hasAuthorship W2020813624A5005263512 @default.
• W2020813624 hasAuthorship W2020813624A5049864482 @default.
• W2020813624 hasAuthorship W2020813624A5080846340 @default.
• W2020813624 hasBestOaLocation W20208136241 @default.
• W2020813624 hasConcept C126322002 @default.
• W2020813624 hasConcept C141341695 @default.
• W2020813624 hasConcept C143998085 @default.
• W2020813624 hasConcept C185592680 @default.
• W2020813624 hasConcept C203014093 @default.
• W2020813624 hasConcept C203092338 @default.
• W2020813624 hasConcept C2522874641 @default.
• W2020813624 hasConcept C2775934546 @default.
• W2020813624 hasConcept C2775940106 @default.
• W2020813624 hasConcept C2777075537 @default.
• W2020813624 hasConcept C2777214474 @default.
• W2020813624 hasConcept C2777382497 @default.
• W2020813624 hasConcept C2777410769 @default.
• W2020813624 hasConcept C2777766500 @default.
• W2020813624 hasConcept C2778019345 @default.
• W2020813624 hasConcept C2779134260 @default.
• W2020813624 hasConcept C2780593183 @default.
• W2020813624 hasConcept C2781197716 @default.
• W2020813624 hasConcept C535046627 @default.
• W2020813624 hasConcept C55493867 @default.
• W2020813624 hasConcept C71924100 @default.
• W2020813624 hasConcept C90924648 @default.
• W2020813624 hasConceptScore W2020813624C126322002 @default.
• W2020813624 hasConceptScore W2020813624C141341695 @default.
• W2020813624 hasConceptScore W2020813624C143998085 @default.
• W2020813624 hasConceptScore W2020813624C185592680 @default.
• W2020813624 hasConceptScore W2020813624C203014093 @default.
• W2020813624 hasConceptScore W2020813624C203092338 @default.
• W2020813624 hasConceptScore W2020813624C2522874641 @default.
• W2020813624 hasConceptScore W2020813624C2775934546 @default.
• W2020813624 hasConceptScore W2020813624C2775940106 @default.
• W2020813624 hasConceptScore W2020813624C2777075537 @default.
• W2020813624 hasConceptScore W2020813624C2777214474 @default.
• W2020813624 hasConceptScore W2020813624C2777382497 @default.
• W2020813624 hasConceptScore W2020813624C2777410769 @default.
• W2020813624 hasConceptScore W2020813624C2777766500 @default.
• W2020813624 hasConceptScore W2020813624C2778019345 @default.
• W2020813624 hasConceptScore W2020813624C2779134260 @default.
• W2020813624 hasConceptScore W2020813624C2780593183 @default.
• W2020813624 hasConceptScore W2020813624C2781197716 @default.
• W2020813624 hasConceptScore W2020813624C535046627 @default.
• W2020813624 hasConceptScore W2020813624C55493867 @default.

• next